Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL)
Candel Therapeutics (NASDAQ: CADL) reported positive extended follow-up results from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer. The immunotherapy, combined with standard radiotherapy, demonstrated a 39% improvement in prostate cancer-specific disease-free survival in the overall population and 41% in the intermediate-risk subgroup, with significant hazard ratios. The treatment was well-tolerated, and Candel plans to submit a Biologics License Application (BLA) in Q4 2026, positioning CAN-2409 as a potential new therapy in over 20 years.
How this was made
The 30-second read
Why it matters
The successful trial outcomes and upcoming BLA submission position CADL as a promising candidate for new prostate cancer therapy, potentially leading to stock appreciation.
Market read
Significant development milestone for CADL with potential to influence biotech investment strategies.
What to watch
Market volatility, broader biotech sector trends, and potential competition from other prostate cancer therapies could influence stock performance.
Background
Candel Therapeutics reported positive extended follow-up results from its Phase 3 trial of aglatimagene besadenovec (CAN-2409) for localized prostate cancer, demonstrating significant improvements in disease-free survival.
Ticker impact
High relevance due to positive clinical trial results and upcoming BLA submission.
Potential 15-25% increase in stock price over the next 3-6 months, contingent on BLA approval.
Strong clinical data, imminent BLA submission, and positive market sentiment support a bullish outlook.
Market effects
Potential catalyst for biotech and immunotherapy sectors.
Primarily US-focused, with possible influence on biotech stocks in North America.
Limited; primarily relevant to US markets and biotech investors.
Counterpoint
Potential delays or setbacks in BLA approval could lead to stock decline; clinical trial data, while positive, does not guarantee regulatory success.
Key entities
- CompanyCandel Therapeutics
Biotech firm developing immunotherapies for cancer.
- Drugaglatimagene besadenovec (CAN-2409)
Immunotherapy showing promising trial results.





